Delayed diagnoses due to pandemic lockdowns tied to years of life lost.
News
Amtagvi is a tumor-derived autologous T cell immunotherapy designed to deploy patient-specific T cells called TIL cells to locate and attack cancer cells.
Findings on PET/CT conducted 1 week after the start of pembrolizumab may predict outcomes of the treatment in patients with advanced melanoma.
Metabolic changes associated with progression-free survival in patients receiving pembrolizumab.
The first medical device powered by artificial intelligence and designed to help doctors catch skin cancer has been approved by the U.S. Food and Drug Administration.
Patients with advanced melanoma can derive a benefit from BRAF/MEK inhibitor rechallenge, new data suggest.
Receiving immunosuppressive therapy before starting immune checkpoint inhibitor treatment may negatively affect survival outcomes in patients with advanced melanoma, new research suggests.
Patients who received the vaccine plus Keytruda were 49 percent less likely to die or have their cancer return after three years.
Lymphedematous extremity 2.65 times as likely as the nonlymphedematous extremity to have skin cancer.
Patients with advanced Merkel cell carcinoma who have achieved a complete response with avelumab may be able to safely discontinue treatment after 1 year.